iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $68.67 million. The enterprise value is -$3.80 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 36.14 million shares outstanding. The number of shares has increased by 688.29% in one year.
| Current Share Class | 36.14M |
| Shares Outstanding | 36.14M |
| Shares Change (YoY) | +688.29% |
| Shares Change (QoQ) | +479.04% |
| Owned by Insiders (%) | 2.36% |
| Owned by Institutions (%) | 38.63% |
| Float | 29.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 228.91 |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.88, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.88 |
| Quick Ratio | 11.50 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -202.51 |
Financial Efficiency
Return on equity (ROE) is -62.09% and return on invested capital (ROIC) is -37.88%.
| Return on Equity (ROE) | -62.09% |
| Return on Assets (ROA) | -34.50% |
| Return on Invested Capital (ROIC) | -37.88% |
| Return on Capital Employed (ROCE) | -36.50% |
| Weighted Average Cost of Capital (WACC) | 10.85% |
| Revenue Per Employee | $15,000 |
| Profits Per Employee | -$1.38M |
| Employee Count | 20 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +135.73% in the last 52 weeks. The beta is 1.24, so iBio, Inc.'s price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | +135.73% |
| 50-Day Moving Average | 1.85 |
| 200-Day Moving Average | 1.66 |
| Relative Strength Index (RSI) | 56.60 |
| Average Volume (20 Days) | 884,428 |
Short Selling Information
The latest short interest is 3.42 million, so 9.45% of the outstanding shares have been sold short.
| Short Interest | 3.42M |
| Short Previous Month | 3.64M |
| Short % of Shares Out | 9.45% |
| Short % of Float | 11.39% |
| Short Ratio (days to cover) | 4.28 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $300,000 and -$27.61 million in losses. Loss per share was -$0.39.
| Revenue | 300,000 |
| Gross Profit | 300,000 |
| Operating Income | -28.96M |
| Pretax Income | -27.61M |
| Net Income | -27.61M |
| EBITDA | -28.27M |
| EBIT | -28.96M |
| Loss Per Share | -$0.39 |
Full Income StatementBalance Sheet
The company has $74.80 million in cash and $2.33 million in debt, with a net cash position of $72.47 million or $2.01 per share.
| Cash & Cash Equivalents | 74.80M |
| Total Debt | 2.33M |
| Net Cash | 72.47M |
| Net Cash Per Share | $2.01 |
| Equity (Book Value) | 77.54M |
| Book Value Per Share | 2.24 |
| Working Capital | 70.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.61 million and capital expenditures -$560,000, giving a free cash flow of -$22.17 million.
| Operating Cash Flow | -21.61M |
| Capital Expenditures | -560,000 |
| Depreciation & Amortization | 688,000 |
| Net Borrowing | -957,000 |
| Free Cash Flow | -22.17M |
| FCF Per Share | -$0.61 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -9,653.00% |
| Pretax Margin | -9,202.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -688.29% |
| Shareholder Yield | -688.29% |
| Earnings Yield | -40.20% |
| FCF Yield | -32.28% |
Analyst Forecast
The average price target for iBio, Inc. is $5.53, which is 191.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.53 |
| Price Target Difference | 191.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 129.70% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
